CDNA vs GRAL: stock comparison and AI forecast
Caredx, Inc. (CDNA) and Grail, Inc. (GRAL) compared on price performance, valuation, profitability and the daily AI forecast. · Alpha · vs market
Share
CDNA Caredx, Inc.
- Market Cap
- $4.52B
- P/E Ratio
- 43.9x
- Size
- mid-cap
- AI Forecast
- NO CURRENT FORECAST
GRAL Grail, Inc.
- Price
- $133.76 +140.3% · 6M
- Market Cap
- $5.97B
- P/E Ratio
- –
- Size
- mid-cap
- AI Forecast
Which one does the AI model favor?
Intratio's model scores both stocks every trading day. Sign in to see their current direction; the exact ratings and forecasts come with a plan or a free follow slot.
Key facts
- GRAL is 1.3 times larger than CDNA by market capitalization ($5.97B against $4.52B).
- CDNA turns 25.9% of its revenue into net income, against -236.9% for GRAL.
- CDNA carries 0.37 times debt per unit of equity, against 0.12 times for GRAL.
- Both companies share the SEC industry classification Services-Medical Laboratories.
Fundamentals side by side
Trailing twelve months.
Valuation & Market
| Metric | CDNA | GRAL |
|---|---|---|
| Market Cap | $4.52B | $5.97B |
| P/E Ratio | 43.93x | – |
| P/B Ratio | 9.67x | 2.35x |
| EPS | $1.99 | $-9.68 |
| Book Value/Share | $9.04 | $56.93 |
| Revenue/Share | $9.61 | $3.70 |
| FCF/Share | – | $-6.63 |
Profitability & Margins
| Metric | CDNA | GRAL |
|---|---|---|
| ROE | 27.5% | -15.4% |
| ROA | 20.1% | -13.8% |
| ROIC | 22.9% | -20.3% |
| Operating Margin | 23.2% | -338.4% |
| Net Margin | 25.9% | -236.9% |
| EBT Margin | 25.0% | -320.4% |
| Tax Rate | -3.5% | 26.0% |
Financial Health
| Metric | CDNA | GRAL |
|---|---|---|
| Current Ratio | 2.31x | 10.95x |
| Quick Ratio | 2.25x | – |
| D/E Ratio | 0.37x | 0.12x |
| Financial Leverage | 1.37x | 1.12x |
| Working Capital | $182M | $831M |
Cash Flow
| Metric | CDNA | GRAL |
|---|---|---|
| Operating Cash Flow | $69M | -$295M |
| Free Cash Flow | – | -$296M |
| Capital Spending | – | -$1M |
| OCF Growth YoY | 62.2% | – |
| FCF/Sales | – | -179.2% |
| CapEx/Sales | – | 0.9% |
Operational Efficiency
| Metric | CDNA | GRAL |
|---|---|---|
| Asset Turnover | 0.78x | 0.06x |
| Receivables Turnover | 10.4x | 8.4x |
| Fixed Assets Turnover | 18.4x | 3.7x |
| Days Sales Outstanding | 35 days | 44 days |
Income Statement
| Metric | CDNA | GRAL |
|---|---|---|
| Total Revenue | $497M | $165M |
| Operating Income | $115M | -$559M |
| Net Income | $129M | -$392M |
| R&D Expense | $84M | $191M |
| SG&A Expense | $344M | $330M |
Dividend & Shareholder Information
| Metric | CDNA | GRAL |
|---|---|---|
| Shares Outstanding | 52M | 45M |
| Net Income Growth | 111.7% | – |
| EPS Growth | 80.9% | – |
CDNA vs GRAL: stock comparison and AI forecast
Which is bigger, CDNA or GRAL?
GRAL is 1.3 times larger than CDNA by market capitalization ($5.97B against $4.52B).
Which one does Intratio's AI model rank higher, CDNA or GRAL?
Intratio's model scores both stocks every trading day. Sign in to see their current direction; the exact ratings and forecasts come with a plan or a free follow slot.
More comparisons
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.